MedTrace Logo

Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults

NCT02333591 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-03-11

No results posted yet for this study

Summary

GLP-1 is an agent for treatment of type 2 diabetes and may have protective effects on the cardiovascular system. The mechanism is complex and there seems to be a dual function with intact GLP-1 (7-36), acting through the GLP-1 receptor, and the GLP-1 (9-36) metabolite acting independently of the GLP-1 receptor.

Coronary flow reserve (CFR) is the ratio of flow through the coronary arteries during stress to during rest and it reflects coronary microcirculation. Impaired CFR is a strong predictor of poor prognosis of cardiovascular disease.

The aim of the study is to investigate the acute effects of GLP-1 on coronary microcirculation and endothelial function in adults with obesity.

Conditions

  • Coronary Microvascular Dysfunction

Interventions

DRUG

GlucagonLikePeptide-1 (7-36)

Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.

DRUG

GlucagonLikePeptide-1 (9-36)

Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.

DRUG

Saline

Infused intravenously for 2,5 hours.

Sponsors & Collaborators

  • Hvidovre University Hospital

    collaborator OTHER

  • Mette Zander

    lead OTHER

Principal Investigators

  • Mette Zander, PhD, MD · Department of Endocrinology, Bispebjerg University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02333591 on ClinicalTrials.gov